| 72.5865 0.147 (0.2%) | 09-14 14:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 96.71 | 1-year : | 104.52 |
| Resists | First : | 82.8 | Second : | 89.48 |
| Pivot price | 76.35  |
|||
| Supports | First : | 71.98 | Second : | 59.89 |
| MAs | MA(5) : | 73.85 |
MA(20) : | 77.82 |
| MA(100) : | 74.68 |
MA(250) : | 70.85  |
|
| MACD | MACD : | -2.1 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 9.9 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 93.41 | Low : | 48.77 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BBIO ] has closed above bottom band by 22.0%. Bollinger Bands are 5.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 74.25 - 74.67 | 74.67 - 75.13 |
| Low: | 70.81 - 71.27 | 71.27 - 71.78 |
| Close: | 71.56 - 72.37 | 72.37 - 73.25 |
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Thu, 10 Sep 2026
BBIO: Late-stage pipeline advances, with differentiated launches and global expansion underway - TradingView
Thu, 10 Sep 2026
BridgeBio Pharma: Attruby Peak Sales Set To Rise - Seeking Alpha
Wed, 09 Sep 2026
BBIO: Multiple late-stage therapies targeting rare genetic diseases set for US launches by 2027 - TradingView
Wed, 09 Sep 2026
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Wed, 09 Sep 2026
A sleep-apnea measure rose 10.4% with an experimental drug, versus 49.2% with placebo - Stock Titan
Mon, 07 Sep 2026
BridgeBio Pharma, Inc. (BBIO) Investor Outlook: Potential 45.77% Upside Amid Robust Pipeline - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 195 (M) |
| Held by Insiders | 1.6718e+008 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 25,750 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.7275e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -97.1 % |
| Return on Assets (ttm) | -44 % |
| Return on Equity (ttm) | -26 % |
| Qtrly Rev. Growth | 7.1307e+008 % |
| Gross Profit (p.s.) | 124.12 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 6.94237e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -434 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 724.4 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.54 |
| Dividend | 0 |
| Forward Dividend | 2.332e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|